美国 · SEC FORM 4
RELMADA THERAPEUTICS, INC.
RLMD · Nasdaq · CIK 0001553643 · Healthcare · Biotechnology
内部人信号
2 位买方 · 4 条买入交易行 · $1.7M 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ 角色得分低 · 买入者中职位最高的是：Chief Executive Officer（CEO、董事长和持股 10% 以上的股东得分最低）
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Chief Executive Officer, Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 62.1
- 62.0
- 62.0
- 61.8
- 61.6
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -16.7%
- 3M
- -47.4%
- 6M
- -53.5%
- 12M
- +59.2%
波动率与流动性
- 波动率
- 139.7%
- Beta
- —
- 平均每日成交额
- USD 4.5M
估值
- 市值
- USD 361.6M
- P/E
- —
基本面
- 利润率
- —
- ROE
- 0.0%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-04 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 13,424,126
- 上期报告
- 14,463,677
- 日均成交量
- 1,033,660
- 回补天数
- 13.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 100,000 | USD 4.10 | USD 410,000 | SEC 申报 ↗ |
| 2026-09-10 | Shenouda Maged | 买入 (P) | Common Stock | 79,800 | USD 4.25 | USD 339,150 | SEC 申报 ↗ |
| 2026-09-09 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 100,000 | USD 4.18 | USD 418,000 | SEC 申报 ↗ |
| 2026-09-09 | Shenouda Maged | 买入 (P) | Common Stock | 120,200 | USD 4.20 | USD 504,840 | SEC 申报 ↗ |
| 2025-12-15 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 27,500 | USD 4.12 | USD 113,300 | SEC 申报 ↗ |
| 2025-12-15 | Shenouda Maged | 买入 (P) | Common Stock | 11,665 | USD 4.12 | USD 48,060 | SEC 申报 ↗ |
| 2025-11-05 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 272,500 | USD 2.20 | USD 599,500 | SEC 申报 ↗ |
| 2025-11-05 | Shenouda Maged | 买入 (P) | Common Stock | 500,000 | USD 2.20 | USD 1,100,000 | SEC 申报 ↗ |
| 2025-11-05 | Kelly Paul Edward | 买入 (P) | Common Stock | 90,000 | USD 2.20 | USD 198,000 | SEC 申报 ↗ |
| 2025-11-05 | Ence Chuck | 买入 (P) | Common Stock | 136,000 | USD 2.20 | USD 299,200 | SEC 申报 ↗ |
| 2025-08-28 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 55,976 | USD 0.74 | USD 41,422 | SEC 申报 ↗ |
| 2025-08-27 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 129,455 | USD 0.67 | USD 86,735 | SEC 申报 ↗ |
| 2025-08-26 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 80,545 | USD 0.62 | USD 49,938 | SEC 申报 ↗ |
| 2025-05-20 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 147,686 | USD 0.56 | USD 82,704 | SEC 申报 ↗ |
| 2025-05-20 | Shenouda Maged | 买入 (P) | Common Stock | 60,000 | USD 0.52 | USD 31,200 | SEC 申报 ↗ |
Form 4 申报证据
10 transaction lines in the latest 365-day window; 164 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 100,000 | USD 4.10 | USD 410,000 | SEC 申报 ↗ |
| 2026-09-10 | Shenouda Maged | 买入 (P) | Common Stock | 79,800 | USD 4.25 | USD 339,150 | SEC 申报 ↗ |
| 2026-09-09 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 100,000 | USD 4.18 | USD 418,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (10 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 100,000 | USD 4.10 | USD 410,000 | SEC 申报 ↗ |
| 2026-09-10 | Shenouda Maged | 买入 (P) | Common Stock | 79,800 | USD 4.25 | USD 339,150 | SEC 申报 ↗ |
| 2026-09-09 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 100,000 | USD 4.18 | USD 418,000 | SEC 申报 ↗ |
| 2026-09-09 | Shenouda Maged | 买入 (P) | Common Stock | 120,200 | USD 4.20 | USD 504,840 | SEC 申报 ↗ |
| 2025-12-15 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 27,500 | USD 4.12 | USD 113,300 | SEC 申报 ↗ |
| 2025-12-15 | Shenouda Maged | 买入 (P) | Common Stock | 11,665 | USD 4.12 | USD 48,060 | SEC 申报 ↗ |
| 2025-11-05 | TRAVERSA SERGIO | 买入 (P) | Common Stock | 272,500 | USD 2.20 | USD 599,500 | SEC 申报 ↗ |
| 2025-11-05 | Shenouda Maged | 买入 (P) | Common Stock | 500,000 | USD 2.20 | USD 1,100,000 | SEC 申报 ↗ |
| 2025-11-05 | Kelly Paul Edward | 买入 (P) | Common Stock | 90,000 | USD 2.20 | USD 198,000 | SEC 申报 ↗ |
| 2025-11-05 | Ence Chuck | 买入 (P) | Common Stock | 136,000 | USD 2.20 | USD 299,200 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RLMD |
| CIK | 0001553643 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 164 transaction lines from 2020-03-17 to 2026-09-10 40 P purchase lines · 81 S sale lines · 43 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.